In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $34.55 in the last session, up 0.82% from day before closing price of $34.27. In other words, the price has increased by $0.82 from its previous closing price. On the day, 0.58 million shares were traded. KYMR stock price reached its highest trading level at $34.99 during the session, while it also had its lowest trading level at $32.75.
Ratios:
We take a closer look at KYMR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.53 and its Current Ratio is at 7.53. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $52.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $60.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $55.BMO Capital Markets initiated its Market Perform rating on December 06, 2024, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Chiniara Ellen sold 2,241 shares for $30.45 per share. The transaction valued at 68,239 led to the insider holds 80,085 shares of the business.
Chadwick Jeremy G sold 1,383 shares of KYMR for $42,113 on Mar 03 ’25. The Chief Operating Officer now owns 67,800 shares after completing the transaction at $30.45 per share. On Mar 03 ’25, another insider, Jacobs Bruce N., who serves as the Chief Financial Officer of the company, sold 7,035 shares for $30.45 each. As a result, the insider received 214,219 and left with 201,886 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2249806080 and an Enterprise Value of 1842836864. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.67 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 39.149 whereas that against EBITDA is -7.35.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.19, which has changed by -0.07620323 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 13.50%, while the 200-Day Moving Average is calculated to be -15.22%.
Shares Statistics:
According to the various share statistics, KYMR traded on average about 708.93K shares per day over the past 3-months and 658670 shares per day over the past 10 days. A total of 64.89M shares are outstanding, with a floating share count of 53.43M. Insiders hold about 17.74% of the company’s shares, while institutions hold 95.06% stake in the company. Shares short for KYMR as of 1744675200 were 7370269 with a Short Ratio of 10.40, compared to 1741910400 on 7842166. Therefore, it implies a Short% of Shares Outstanding of 7370269 and a Short% of Float of 12.67.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Kymera Therapeutics Inc (KYMR) is currently drawing attention from 14.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.76 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$2.61 and -$4.72 for the fiscal current year, implying an average EPS of -$3.73. EPS for the following year is -$4.32, with 14.0 analysts recommending between -$3.13 and -$5.99.
Revenue Estimates
According to 17 analysts, the current quarter’s revenue is expected to be $10.73M. It ranges from a high estimate of $20M to a low estimate of $1.6M. As of the current estimate, Kymera Therapeutics Inc’s year-ago sales were $10.29MFor the next quarter, 17 analysts are estimating revenue of $12.38M. There is a high estimate of $30.1M for the next quarter, whereas the lowest estimate is $4M.
A total of 19 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $140M, while the lowest revenue estimate was $13.6M, resulting in an average revenue estimate of $60.1M. In the same quarter a year ago, actual revenue was $47.07M
